Search clinical trials for: GSK2256098

Total 12 results

GlaxoSmithKline

Completed

Phase I Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2256098 in Healthy Volunteers (FTIH)

Cancer

Australia
GlaxoSmithKline

Completed

Study of a Focal Adhesion Kinase Inhibitor in Subjects With Solid Tumors

Cancer

Australia, United Kingdom, France
GlaxoSmithKline

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2256294 in Healthy Volunteers, and Single and Repeat Doses of GSK2256294 in Adult Male Moderately Obese Smokers

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of GSK2256294 in Healthy Young Males and Elderly Subjects

Pulmonary Disease, Chronic Obstructive

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); GlaxoSmithKline; Genentech, Inc.; Brain Science...

Recruiting

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Intracranial Meningioma | Recurrent Meningioma | NF2 Gene Mutation

United States
Oregon Health and Science University
GlaxoSmithKline; Foundation for Anesthesia Education and Research

Completed

Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial (SUSHI)

Endothelial Dysfunction | Subarachnoid Hemorrhage, Aneurysmal | Delayed Cerebral Ischemia | Vasospasm, Cerebral

United States
GlaxoSmithKline
Parexel

Completed

To Evaluate Effects of GSK2256294 on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients

Hypertension, Pulmonary

United Kingdom
Vanderbilt University Medical Center
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...

Completed

Soluble Epoxide Hydrolase Inhibition and Insulin Resistance

Glucose Metabolism Disorders | Obesity | Diabetes Mellitus | Endocrine System Diseases | PreDiabetes

United States
GlaxoSmithKline

Completed

A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors

Neoplasms | Cancer

United Kingdom, France
University Health Network, Toronto
GlaxoSmithKline

Completed

A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer

Adenocarcinoma | Pancreatic Cancer

Canada
Axcan Pharma
AAIPharma; Mayo Clinical Services; City Hospital Laboratory Birmingham

Completed

An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exocrine Pancreatic Insufficiency (EPI)

Exocrine Pancreatic Insufficiency

United States

Search clinical trials for: GSK2256098

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations